Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 5, 2004 Charly Travers	A Biotech's Transition to Drugs A deal with Roche gives ArQule's drug program a leg up. ArQule has spent the last year transitioning from a services company into a drug developer. Last week's deal with Roche could signify that the transition is complete.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool August 8, 2007 Brian Lawler	Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline.
The Motley Fool May 22, 2007 Brian Lawler	Elan Plunges Ahead Shares of the drugmaker Elan have climbed more than 20% in the past two days after the company announced that it and partner Wyeth were moving their lead Alzheimer's disease treatment into phase 3 testing.
The Motley Fool March 31, 2008 Brian Lawler	A Little Funding for Pharmasset Development-stage drugmaker Pharmasset may be on to something with its hepatitis C compounds.
The Motley Fool December 21, 2010 Brian Orelli	4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool August 31, 2007 Brian Lawler	4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals.
The Motley Fool January 16, 2008 Brian Lawler	Talking With a Development-Stage Pharma An interview with Dr. Leslie Browne, CEO of development-stage drugmaker Pharmacopeia.
The Motley Fool April 23, 2008 Brian Orelli	Wyeth Recovers From Its Heartburn Wyeth deals with generic competition for one of its biggest drugs.
BusinessWeek November 14, 2005 Gene G. Marcial	Rivals Are Eyeing Wyeth Drugmaker Wyeth is the most attractive in the beleaguered pharma sector.
Bio-IT World February 2007 Kevin Davies	Ten Years After: Learn and Confirm Wyeth faces the same problems bedeviling the industry: the soaring cost of development is matched only by the rising attrition rate as once promising drug candidates fall by the wayside. But a new strategy leads to a more science-driven model.
The Motley Fool October 19, 2007 Billy Fisher	Wyeth's Resilience Wyeth's latest quarter is an outstanding example of the drugmaker's consistency; the company reports solid results from all of its businesses, along with a 9% increase in sales.
Fast Company February 2009 Elizabeth Svoboda	Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits.
The Motley Fool October 19, 2006 Brian Lawler	A Yawn and More Growth From Wyeth Investors, the numbers aren't all that new, but they are good. With its guidance of $3.12 to $3.18 in EPS for the year and a steadily increasing dividend, Wyeth is a good candidate for investors who want to get a start in this sector
The Motley Fool January 30, 2007 Brian Lawler	Wyeth's Slow Growth Wyeth releases its 2006 financial results and guides for another year of slow growth. Investors, take note.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool April 20, 2005 Stephen D. Simpson	Wyeth Looking Healthier Improving sales are helping this troubled drugmaker recover a little faster. Big pharma investors might see Wyeth as one of the more interesting growth and turnaround candidates in the industry.
Bio-IT World January 13, 2003 John Dodge	Managing Innovation and Adversity ArQule CIO Alan Hillyard's database migration project became more challenging -- and more important -- following recent layoffs. The good news is that progress continues.
The Motley Fool August 3, 2007 Billy Fisher	Stormy Waters at Wyeth The downward trend in the price of Wyeth shares may have painted a grim picture for the stock's future; however, the company has already demonstrated its ability to grow revenues despite the competition from generics.
BusinessWeek February 6, 2006 Amy Barrett	Cracking The Whip At Wyeth Wyeth's R&D chief Robert Ruffolo imposed tough targets on scientists - and it's working.
The Motley Fool October 6, 2006 Brian Lawler	Wyeth Makes Investors Happy It's facing some challenges, but there's a lot for investors to like about this drug company.
The Motley Fool October 8, 2007 Billy Fisher	Wheeling and Dealing at Wyeth A busy day at Wyeth. The company plans to submit a New Drug Application to the FDA, and acquires biopharmaceutical firm Haptogen.
Pharmaceutical Executive October 1, 2006 Clinton & Koroneos	Learn & Confirm At Wyeth, a sweeping set of initiatives is transforming the R&D operation - and spotlighting a possible future for drug development.
The Motley Fool July 20, 2007 Billy Fisher	Wyeth Keeps Working Its Magic The drugmaker's second-quarter boasts 12% earnings growth. Of particular promise was the reversal over first-quarter for its top seller, the antidepressant Effexor.
The Motley Fool July 20, 2005 Karl Thiel	Pride and Preclinicals Biotech ArQule has surged, but take its early-stage data with a grain of salt.
The Motley Fool October 21, 2005 Stephen D. Simpson	Is Wyeth Your Happy Pill? The pharma has crawled back from scandal, but growth prospects aren't looking so healthy. Investors should not be in a hurry to pay a premium for these shares today.
The Motley Fool April 21, 2006 Stephen D. Simpson	Wily Wyeth For the most part, this business will produce high-single-digit revenue growth, and hopefully low-teens growth in earnings and cash flow. That means investors should be a little conservative buying in, but patient when holding.
The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
The Motley Fool May 30, 2008 Brian Orelli	No Love for Antibiotics From the FDA Wyeth gets an approvable letter for its antibiotic Tygacil.
The Motley Fool April 27, 2009 Jim Mueller	Foolish Forecast: Pfizer's Out of the Starting Gate In advance of earnings, analyst's expect revenue down 6%, but none are saying to dump the stock.
Chemistry World January 27, 2009 Matt Wilkinson	Pfizer's Wyeth injection Pfizer has agreed to pay $68 billion ( 48.3 billion) for rival US biopharmaceutical firm Wyeth, gaining access to its rich product portfolio and promising pipeline of experimental drugs.
The Motley Fool July 2, 2004 Brian Gorman	Muscle in Wyeth's Pipeline An early stage Wyeth drug may have a better-than-average chance of approval.
The Motley Fool September 20, 2007 Billy Fisher	More Options for Healthy Bones? Novartis and Wyeth might be able to offer alternative treatments for osteoporosis, but the companies have a tough road ahead in this market.
The Motley Fool June 22, 2004 Charly Travers	Merck Pays Up for a Cancer Drug As demonstrated this morning with the announcement of a major deal with Vertex Pharmaceuticals, Merck is now in the midst of a strategic push to build out its oncology pipeline.
The Motley Fool May 19, 2009 Brian Orelli	The Cherry on Pfizer's Acquisition Sundae Pfizer may inherit a lawsuit.
The Motley Fool January 22, 2004 Alyce Lomax	Worries for Wyeth Despite pain-free vaccine, the drug maker's results are still painful.
The Motley Fool April 20, 2007 Billy Fisher	Many Ways to Feel Good About Wyeth The drugmaker's pipeline makes investors look forward to the next few quarters, too.
The Motley Fool July 25, 2008 Brian Orelli	Generic Heartburn at Wyeth Revenue from its heartburn drug Protonix dropped 59% year over year after Teva Pharmaceuticals and Sun Pharmaceuticals launched their generic versions of the drug.
The Motley Fool September 22, 2008 Brian Orelli	Ouch, That's Gotta Hurt! Acupuncture beats Wyeth's Effexor in stopping hot flashes.
The Motley Fool December 15, 2004 Brian Gorman	Wyeth Keeps Producing The drug maker's difficulties are evident, but its productivity may make it worth an investor's second look.
The Motley Fool June 21, 2005 Brian Gorman	Wyeth's Lower Dosage The company's planned sales-force cutback shows its resolve to increase efficiency. Investors, this pharmaceutical remains the one to watch.
The Motley Fool March 28, 2008 Brian Orelli	Wyeth Fires to Get Back on Fire The first round of Wyeth's cuts look like the right move for the big pharma company.
The Motley Fool June 28, 2005 Stephen D. Simpson	A Boost for Wyeth Wyeth raises full-year expectations for the second time. Perhaps this is a peek at what's to come for investors in other pharmaceuticals, too.
The Motley Fool March 7, 2008 Brian Orelli	A Heavy Price for Wyeth and Pfizer They're ordered to pay millions because their hormone therapies may carry a higher risk of breast cancer.
The Motley Fool August 13, 2007 Andrew R. Vaino	Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow.
The Motley Fool September 24, 2009 Brian Orelli	Wyeth's Biting the Hand That Feeds It Wyeth decides to sue the Food and Drug Administration after it approved Orchid Chemicals & Pharmaceuticals' generic version of its antibiotic Zosyn.
Bio-IT World October 2006	Briefs Kovac Joins Burrill... RNAi Nobel Prize... Hooray for Hood... ArQule Next... Initiative Accelerated...
The Motley Fool January 31, 2005 Stephen D. Simpson	Wyeth's Waiting Game The end of diet-drug litigation may be in sight, but growth hasn't recovered yet. Anyone holding or looking to buy these shares needs to understand that it will take time to get growth back on track, and there could be setbacks along the way.
The Motley Fool January 26, 2009 Brian Orelli	Deja Vu All Over Again There's hardly anything to like about Pfizer's deal to buy Wyeth. This is what got Pfizer into its problem in the first place.